Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 25.68% | -- |
POINT Biopharma Global Inc | 43.97% | 1.38bn |
Versanis Bio Inc | 78.28% | 1.93bn |
Emergence Therapeutics AG | 68.96% | 8.33m |
Sigilon Therapeutics Inc | 68.96% | 316.64m |
Data delayed at least 15 minutes, as of May 08 2024 21:10 BST.